Front-line Treatment with Ofatumumab in Elderly Unfit Patients with CLL

Abstract

S26 had an alternative diagnosis for their neurologic symptoms identified after tissue biopsy and/or other work-up. On LP, lower glucose levels (median 54 mg/dL, p1⁄40.02), elevated total nucleated cells (TNC)(median 14/mL, p1⁄40.004), absolute lymphocyte count (ALC) (median 12/mL, p1⁄40.02), CLL cells percentage (median 5%, p1⁄40.05) and count (median 1.5/mL, p1⁄40.02) significantly associated with a final diagnosis of CNS involvement CLL/RS. Despite this association, none reliably discriminated as to whether the etiologies of patients’ neurologic symptoms were due to clinically significant CNS involvement by CLL/RS or another etiology. Conclusions: Neurological symptoms requiring an LP are rare in patients with CLL/SLL (4% of cases). CNS CLL/RS is a rare condition, and neurologic symptoms in patients with CLL are attributable to other etiologies in w80% of cases. Analysis of the CSF has high sensitivity but limited specificity to distinguish CNS CLL from other etiologies and additional parameters are needed. 306 Front-line Treatment with Ofatumumab in Elderly Unfit Patients with CLL Candida Vitale, Maria Ciccone, Christina Hinojosa, Michael J. Keating, Naveen Pemmaraju, Susan O’Brien, William G. Wierda, Deborah Thomas, Gautam Borthakur, Maro Ohanian, Jan A. Burger, Alessandra Ferrajoli Department of Leukemia, The University of Texas MD Anderson